EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting PI3Kα increases the efficacy of anti‐PD ‐1 antibody in cervical cancer

Wei Jiang, Xueyan Ouyang iD, Chunyan Li, Yixiu Long, Wei Chen, Zhaodong Ji, Xuxia Shen, Libing Xiang, Huijuan Yang

Immunology · 2023-11 · 170 (3) · 419-438

DOI: 10.1111/imm.13682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 19.07.2023. Verfasst von Wei Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Health and Family Planning Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting programmed death 1(PD‐1) has been approved for relapsed cervical cancer with unsatisfactory clinical efficacy. This study aims to analyse the impact of PI3K pathway activation on tumour immune microenvironment and evaluates the immune sensitization effect by PI3K inhibition in cervical cancer. The effect of PIK3CA mutation on PD‐L1 expression and CD8+ T cells differentiation was determined in cervical cancer tissues. Luciferase and ChIP‐qPCR/PCR assays were used to determine the transcriptional regulation of PD‐L1 by PIK3CA ‐E545K. The effects of PI3K inhibitor treatment on immune environment in vitro and in vivo were evaluated by RNA sequencing (RNA‐seq) and flow cytometry. The efficacy of PI3K inhibitor and anti‐PD‐1 therapy was assessed in cell‐derived xenografts (CDX) and patients‐derived xenografts (PDX). PD‐L1 overexpression is more frequently observed in elder women with squamous cervical carcinoma. It predicts longer progress‐free survival and overall survival. PIK3CA mutation results in increased mRNA and protein levels of PD‐L1, the repression of CD8+ T cell differentiation in cervical cancer. Here, we report a case that continuous pembrolizumab monotherapy treatment induced complete remission of a recurrent cervical cancer patient with systemic metastasis and PIK3CA ‐E545K mutation, implying that PIK3CA mutation is potentially a biomarker for pembrolizumab treatment in cervical cancer. Specifically, this mutation promotes the expression of PD‐L1 by upregulating the transcription factor IRF1. PI3Kα‐specific inhibitor markedly activates immune microenvironment by regulating the PD‐1/L1‐related pathways and promoting CD8+ T cell differentiation and proliferation in Caski‐CDXs with PIK3CA ‐E545K mutation. PI3Kα inhibitor significantly enhances the anti‐tumour efficacy of PD‐1 blockade in CDXs and PDXs. PIK3CA mutations may predict the response of cervical cancer to PD‐1 blockade. The efficacy of PI3Kα inhibitors combined with PD‐1 antibodies is promising in cervical cancer and warrants additional clinical and mechanistic investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsHumansFemaleAgedB7-H1 AntigenProgrammed Cell Death 1 ReceptorPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesTumor Microenvironment

Stichwörter der Autor:innen

PD-1/L1PIK3CA mutationcervical cancerimmune checkpoint blockade

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Obstetrics and Gynecology, Minhang Hospital, Fudan University, the Central Hospital of Minhang District, Shanghai, China.
  • Department of Clinical Laboratory, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Pathology Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Xueyan Ouyang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Health and Family Planning Commission
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Jiang, W., Ouyang, X., Li, C., Long, Y., Chen, W., Ji, Z., Shen, X., Xiang, L., & Yang, H. (2023). Targeting PI3Kα increases the efficacy of anti‐PD ‐1 antibody in cervical cancer. Immunology, 170(3), 419-438. https://doi.org/10.1111/imm.13682

Vancouver

Jiang W, Ouyang X, Li C, Long Y, Chen W, Ji Z, et al. Targeting PI3Kα increases the efficacy of anti‐PD ‐1 antibody in cervical cancer. Immunology. 2023;170(3):419-438. doi:10.1111/imm.13682

BibTeX
@article{Jiang2023,
  author = {Jiang, Wei and Ouyang, Xueyan and Li, Chunyan and Long, Yixiu and Chen, Wei and Ji, Zhaodong and Shen, Xuxia and Xiang, Libing and Yang, Huijuan},
  title = {Targeting PI3Kα increases the efficacy of anti‐PD ‐1 antibody in cervical cancer},
  journal = {Immunology},
  year = {2023},
  volume = {170},
  number = {3},
  pages = {419--438},
  doi = {10.1111/imm.13682}
}
Kostenlos starten →